Emcure Pharmaceuticals Share Price Jumps 4% on Monday; Here's Why

On Monday, Indian equity benchmarks traded lower, with the benchmark Nifty 50 index declining 95.80 points, or 0.39 per cent, to 24,238.50. Despite the weak broader market sentiment, Emcure Pharmaceuticals share price gained 4.37 per cent to Rs 1,861.20, rising Rs 78.00, after the company announced the expansion of its semaglutide-based therapy, Poviztra®, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) following regulatory approval.

Emcure Expands Poviztra® for MASH Treatment

Emcure Pharmaceuticals announced that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following the Central Drugs Standard Control Organisation (CDSCO) approval of Wegovy® for the indication.

According to the company, the approval makes Novo Nordisk's innovator molecule the first and only GLP-1 receptor agonist approved in India for the treatment of MASH. Poviztra® is manufactured and imported from Novo Nordisk's European manufacturing facility, enabling Emcure to expand access to innovator semaglutide for patients suffering from this progressive liver disease.
Also Read - Best Performing Mid Cap Mutual Funds: Top 5 Schemes Based on 1-Year Returns

Addresses a Significant Unmet Medical Need

MASH is a progressive liver disease caused by excess fat accumulation in the liver, leading to chronic inflammation, fibrosis and liver damage. The disease is closely associated with obesity, type 2 diabetes and other metabolic disorders and often remains undiagnosed until advanced stages.

The approval is supported by findings from the global Phase III ESSENCE trial, in which semaglutide achieved resolution of steatohepatitis in 63 per cent of patients and improved liver fibrosis in 37 per cent of patients. Additionally, one in three patients achieved both resolution of steatohepatitis and improvement in liver fibrosis, highlighting the therapy's potential to address the underlying disease.

Management Commentary

Commenting on the development, Satish Mehta, Chief Executive Officer & Managing Director, Emcure Pharmaceuticals Limited, said: "The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease. We are pleased to make this important new indication available through Poviztra®, further strengthening our commitment to bringing globally validated, innovative therapies to patients in India. We look forward to working closely with healthcare professionals to improve awareness, encourage earlier diagnosis and expand access to evidence-based treatment for people living with MASH."

Strengthening the Metabolic Care Portfolio

The company stated that Poviztra® has already established its presence in chronic weight management for people living with obesity and overweight individuals with co-morbid conditions such as hypertension, dyslipidaemia and type 2 diabetes. The therapy is also approved for obese patients with established cardiovascular disease and for the management of adolescent obesity in patients aged 12 years and above.

The addition of the MASH indication further strengthens Emcure's strategy of addressing complex metabolic diseases through innovative, science-led therapies while supporting improved long-term patient outcomes.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an R&D-driven Indian pharmaceutical company engaged in the development, manufacturing and global marketing of a broad portfolio of pharmaceutical products. Headquartered in Pune, the company operates across several major therapeutic areas and has a presence in more than 70 countries, including Europe and Canada.

Established in 1981, Emcure ranked as the 13th largest pharmaceutical company in India in terms of domestic sales for the twelve months ended March 2026.

What are your views on Emcure Pharmaceuticals' latest regulatory approval? Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and should not be construed as investment advice.